This clinical trial is being done in people with Chronic thromboembolic pulmonary hypertension, a form of high blood pressure in the lungs caused by old blood clots. The study compares two medicines given by intravenous infusion after pulmonary endarterectomy, an operation that removes clots from the lung arteries. The medicines are argipressin in Reverpleg 40 U.I./2 ml and noradrenaline tartrate in NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES. The purpose of the study is to see which medicine works better for lowering pressure in the lung arteries soon after surgery.
After the operation, each person receives one of the two medicines through a vein. The treatment is given in the recovery period after surgery, and the medical team follows the person during the hospital stay to watch how the heart, lungs, kidneys, and other organs recover. The study is open label, which means the treatment is known to the medical team and the person receiving it.
The main outcome is the change in mean pulmonary arterial pressure, which is the pressure in the main blood vessel carrying blood from the heart to the lungs. Other hospital problems may also be watched, such as kidney failure, atrial fibrillation or atrial flutter (irregular heart rhythms), stroke, pneumonia, bleeding from the airways, and death. The study is planned to run over several years while enough people are enrolled and followed after surgery.
France 
